Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
September 29, 2021 07:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma - Health Canada Issues...
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD
June 24, 2021 08:30 ET
|
Helsinn Healthcare S.A.
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical...
Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan
April 21, 2021 02:30 ET
|
Helsinn Healthcare S.A.
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building...
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV
April 13, 2021 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV Lugano, Switzerland, April 13, 2021 – Helsinn,...
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
March 31, 2021 07:30 ET
|
Helsinn Healthcare S.A.
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through its Affiliate QED...
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
March 18, 2021 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
February 18, 2021 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
January 22, 2021 01:39 ET
|
Helsinn Healthcare S.A.
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media ...